



State-of-the-Art Immunology and Immunotherapy in Europe

Guest Editor:

Dr. Juan Gambini

Freshage Research Group,
Department of Physiology,
Faculty of Medicine, University of
Valencia, E46010 Valencia, Spain

Deadline for manuscript
submissions:

closed (31 December 2023)

Message from the Guest Editor

Dear Colleagues,

Immunity represents one of the main pillars of longevity. The risk of suffering from diseases decreases in individuals with a more effective immune system. Why do individuals who reach 100 years of age have such powerful immunity? This depends innately on our genetics. Stress, vaccines, drugs, etc., will also positively or negatively influence our immune system and, therefore, our health. In this Special Issue, we plan to collect studies that describe the behavior of the immune system and explore how to modulate it so that it is our own body that cures us of diseases and allows us to live a healthier life in old age.

Prof. Dr. Juan Gambini

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding

Rehabilitation Hospital and

Massachusetts General Hospital,

Harvard Medical School, Boston,

MA 02114, USA

2. Department of Epidemiology,

Harvard T.H. Chan School of

Public Health, Boston, MA 02115,

USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)